GeS, WangY, SongM, et al. (2018). Type 2 diabetes mellitus: Integrative analysis of multiomics data for biomarker discovery. OMICS, 22, 514–523.
2.
JamesA, HunterM, StrakerL, et al. (2013). Rationale, design and methods for a community-based study of clustering and cumulative effects of chronic disease processes and their effects on ageing: The Busselton healthy ageing study. BMC Public Health, 13, 936.
3.
MenniC, GudeljI, MacDonald-DunlopE, et al. (2018). Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. Circ Res, 122, 1555–1564.
4.
PlompR, RuhaakL, UhHW, et al. (2017). Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep, 7, 12325.
5.
RussellA, AduaE, UgrinaI, LawsS, and WangW. (2018). Unravelling immunoglobulin G Fc N-glycosylation: A dynamic marker potentiating predictive, preventive and personalised medicine. Int J Mol Sci, 19, 390.
6.
RussellA, KepkaA, Trbojević-AkmačićI, et al. (2019). Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology, 224, 110–115.
7.
SegmanR, and SteinM. (2015). C-reactive protein: A stress diathesis marker at the crossroads of maladaptive behavioral and cardiometabolic sequelae. Am J Psychiatry, 172, 307–309.
8.
WangY, KlaricL, YuX, et al. (2016). The association between glycosylation of immunoglobulin G and hypertension: A multiple ethnic cross-sectional study. Medicine, 95, e3379.
